NCT02113631View on ClinicalTrials.gov

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Hepatitis C, ChronicCirrhosis
Interventions
DRUG

Telaprevir

DRUG

Boceprevir

DRUG

Peg-IFN

Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks

DRUG

Ribavirin

Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks

Trial Locations (1)

44106

Louis Stokes Cleveland VA medical center, Cleveland

All Listed Sponsors
lead

Louis Stokes VA Medical Center

FED

NCT02113631 - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir | Biotech Hunter | Biotech Hunter